Are These New Diabetes Drugs Defective?

Picture of Prescription MedicationThe FDA has issued a warning on a new class of diabetes medications called sodium-glucose cotransporter-2 (SGLT2). This new class of drug was approved for use in 2013 and treats type-2 diabetes by stimulating the kidneys into releasing more sugar from blood into urine. Drugs of this type include: Invokana, Invokamet, Farxiga, Xigduo XR, Jardiance, and Glyxambi.

The FDA has received at least 20 reports of these types of drugs allegedly triggering a condition known as ketoacidosis. Ketoacidosis happen when too many acids, known at ketones, build up in the blood stream. The condition can cause difficulty breathing, nausea, vomiting, abdominal pain, confusion, and fatigue or sleepiness. If left untreated, ketoacidosis can also cause diabetic coma or even death.

What Can I Do If I’m Taking One of These Diabetes Drugs?

If you are experiencing any of the symptoms described above and you happen to take any of the SGLT2 medications mentioned, contact your doctor. The side-effects that SGLT2 drugs may cause can be very dangerous, and if you have been hurt or a loved one has died as a result of one of these side-effects, you need to speak to a lawyer immediately.

Our Louisiana attorneys have experience dealing with pharmaceutical companies that release products that harm patients. Visit our defective drugs page for more information about how we’ve helped other victims of prescription medication injuries. Also keep an eye on our Facebook, Twitter, and blog for the latest information and news concerning threats to your health and safety.

Galloway Jefcoat LLPPersonal Injury Attorneys in Lafayette, LA


One Response to Are These New Diabetes Drugs Defective?

  1. Jordan Jordan says:

    Great reminder for those dealing with diabetes to keep in mind. Sometimes drugs have more than just tolerable side effects – in cases like that, getting in contact with a lawyer AND your doctor is key.

Leave a Reply

Your email address will not be published. Required fields are marked *